[go: up one dir, main page]

WO2012032043A1 - Imagerie 212 pb - Google Patents

Imagerie 212 pb Download PDF

Info

Publication number
WO2012032043A1
WO2012032043A1 PCT/EP2011/065388 EP2011065388W WO2012032043A1 WO 2012032043 A1 WO2012032043 A1 WO 2012032043A1 EP 2011065388 W EP2011065388 W EP 2011065388W WO 2012032043 A1 WO2012032043 A1 WO 2012032043A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
antibody
cancer cell
antibodies
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2011/065388
Other languages
English (en)
Inventor
Michael Azure
Gilbert Andreoletti
Patrick Maquaire
Julien Torgue
Patrick Bourdet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orano Med LLC
Original Assignee
Areva Med LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Areva Med LLC filed Critical Areva Med LLC
Publication of WO2012032043A1 publication Critical patent/WO2012032043A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies

Definitions

  • Radioimmunotherapy in certain instances consists of irradiating cancerous cells present in an organism by injecting a monoclonal antibody conjugated to a radioisotope emitting alpha or beta particles which selectively binds to an antigen present predominantly on cancerous cells. Radioimmunotherapy is intended for the treatment of disseminated cancers, such as metastatic cancer, and for the treatment of micrometastases.
  • 212 Bi which is an alpha-emitter
  • 212 Pb which is a beta-emitter and the radioactive parent of 212 Bi
  • the preparation of radiopharmaceutical products which comprise these descendants involves firstly being able to provide, and therefore to produce on an industrial scale
  • radioisotopes such as Ra
  • the parent of Pb the parent of Pb.
  • the invention relates to a pharmaceutical and/or diagnostic composition comprising of an
  • the targeting molecule is a polypeptide, including an antibody.
  • the antibody may immunospecifically bind to one or more antigens selected from the group consisting of: HER2, HER1, CD45, CD25, CD20, CD22, CD19, CD33, VEGF, MET, CEA, BRCA1, BRCA2 and IGFR.
  • the targeting molecule is a liposome.
  • effective amount is an amount effective to image a malignant cancer cell or pathogen.
  • the metastatic cancer cell is a micrometastatic cancer cell.
  • the metastatic cancer cells may or may not be present in a solid tumor.
  • the pathogen is a virus or bacterium.
  • the pharmaceutical and/or diagnostic composition is substantially
  • Substantially free may be defined such that the amount of Ra present in the composition is less than 0.5% of the total 212 Pb. Substantially free may be further defined such
  • substantially free may be defined such that the amount of 224 Ra present in the
  • 212 224 composition is less than 0.25% of the total Pb where 0.25% represents less than one Ra molecule per 400 molecules of 212 Pb.
  • the polypeptide present in the pharmaceutical and/or diagnostic composition is conjugated to said 212 Pb via a chelator.
  • chelators include, but are not limited to, TCMC and DOTA.
  • the invention also encompasses a method for imaging a malignant cancer cell or pathogen in a mammal, comprising administering any of the above pharmaceutical and/or diagnostic compositions in an amount sufficient to resolve gamma irradiation emitted by the 212 Pb and/or its decay products.
  • the malignant cancer cell is metastatic and includes, but is not limited to, a malignant cancer cell which is present in micrometastases.
  • the malignant cancer overexpresses a cell surface marker selected from the group consisting of HER2, HERl, CD45, CD25, CD20, CD22, CD 19, CD33, VEGF, MET, CEA, BRCA1, BRCA2 and IGFR whereas the pathogen may be a virus or bacterium.
  • the mammal is a human.
  • the decay product referenced above may be selected from the group consisting of 212 Bi and 208 T1.
  • Figure 1 (a) NHP phantom organs; (b) assembled phantom placed on SPECT camera.
  • the top 30 mL vial represents the heart, the center 250 mL saline bag the liver, and the two lower 15 mL vials the kidneys.
  • Medium energy collimators are mounted on SPECT camera for all imaging.
  • Figure 2 (a) NHP phantom images containing 2.8 MBq (75 ⁇ ) in the heart, 3.2 MBq
  • FIG. 3 Planar gamma camera images of the phantom (peritoneal) with threshold adjustment together with a photograph of the phantom during imaging at 0 hour. The collimator is visible below. Small sources are located above the arrowheads to check orientation.
  • Figure 4 Planar gamma camera images of dose residual syringe with threshold adjustment and regions of interest.
  • Figure 5 Planar gamma camera images of NHP-1 with threshold adjustment.
  • Figure 6 (a) Planar Images Collected on ⁇ 8 ⁇ / ⁇ of three separate mice post- intraperitoneal injection of 212 Pb-TCMC-Trastuzumab at time points of to, h, and t 8h ; (b) ⁇ 8 ⁇ / ⁇ images of a single mouse collected at post-intraperitoneal injection of 212 Pb-TCMC- Trastuzumab at time points of to, Uh, and t 8h .
  • Radiation is an effective cancer treatment, but it is difficult to direct and can be devastating to non-targeted parts of the body. Indeed, treatments are often limited by radiation's non-selectivity, resulting in toxicity on the normal tissues.
  • agents which target malignant cancer cells selectively target diseased cells, limiting harmful exposure to nearby healthy cells. The ability of these agents to exploit antigenic differences between normal and malignant tissues and to exact a variety of anti-tumor responses offers significant advantages over conventional forms of imaging and therapy.
  • Radioimmunotherapy and radioimaging which incorporate conjugating a radioisotope to an agent which selectively targets a malignant cancer cell, can solve both problems.
  • agents such as monoclonal antibodies, are highly specific and can be used as vehicles to deliver substances to specific target sites.
  • the conjugation of these agents to a radioisotope is an effective way of targeting specific cells, thus reducing the side effects of radiotherapy.
  • the present invention is a radiopharmaceutical composition that comprises a radioactive isotope of lead ( 212 Pb), in combination with a pharmaceutical or an antibody or antibody fragment, and a bifunctional chelating agent.
  • the present invention includes the use of any monoclonal antibody which exhibits cell-binding or antigen-binding capability.
  • compositions that comprise a targeting agent, which specifically binds to a cell surface marker on a malignant cancer cell, wherein said agent is
  • compositions of the invention can be used for imaging a tumor in a mammal, including a human, but can also be used for imaging a tumor in non-humans, including but not limited to, mice, rats, sheep, cattle, horses, monkeys, dogs and cats.
  • 212 Pb has very favorable nuclear and chemical properties, and can be conjugated via a metal chelator to monoclonal antibodies.
  • the resulting conjugate administered through intravenous or intraperitoneal injection of the 212 Pb radioisotope antibody conjugate, has been used in vivo to image and assess the biodistribution of the antibody.
  • the development and production of monoclonal antibodies is well known and has been extensively discussed.
  • the present invention includes the use of any monoclonal antibody which exhibits cell binding or antigen binding capability.
  • the selection and production of suitable monoclonal antibodies is within the skill of the art.
  • the antibody or antibody fragment used in this invention may be any polyclonal or monoclonal antibody or antibody fragment which forms an immunochemical reaction with an antigen.
  • An "antigen” as used herein includes any substance or molecule which induces the formation of an antibody (i.e. , that can trigger an immune response), and can be a virus, a bacterium, a fungus, a parasite, tissues or cells not naturally a member of a host's family of tissues or cells, or even a portion or product of any of these organisms.
  • Antigenic or “immunogenic” are used to describe the capacity of a given substance to stimulate the production of antibodies.
  • antibody as used herein includes the soluble substance or molecule secreted or produced by an animal in response to an antigen, and which has the particular property of combining specifically with the antigen which induced its formation.
  • Antibodies also known as immunoglobulins, are classified into five distinct classes: IgG, IgA, IgM, IgD, and IgE.
  • the basic IgG immunoglobulin structure consists of two identical light polypeptide chains and two identical heavy polypeptide chains (linked together by disulfide bonds). When IgG is treated with the proteolytic enzyme papain, an antigen binding fragment (or Fab) can be isolated.
  • An antibody is further defined to include a heterotetrameric glycoprotein composed of two identical light (L) chains and two identical heavy (H) chains
  • an IgM antibody consists of five of the basic heterotetramer units along with an additional polypeptide called J chain, and therefore contains ten antigen binding sites, while secreted IgA antibodies can polymerize to form polyvalent assemblages that comprise two to five of the basic four-chain units along with J chain.
  • the L chain from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda, based on the amino acid sequences of their constant domains, and the methods of the current invention include the use of antibodies with either a kappa or lambda L chain.
  • immunoglobulins can be assigned to different classes or isotypes. There are five classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, having heavy chains designated alpha, delta, epsilon, gamma and mu, respectively.
  • the gamma and alpha classes are further divided into subclasses on the basis of relatively minor differences in C H sequence and function, e.g. , humans express the following subclasses: IgGl, IgG2, IgG3, IgG4, IgAl and IgA2.
  • variable refers to the fact that certain segments of the variable domains differ extensively in sequence among antibodies.
  • the variable domain mediates antigen binding and defines specificity of a particular antibody for its particular antigen.
  • variability is not evenly distributed across the 110-amino acid span of the variable domains.
  • the variable regions consist of relatively invariant stretches called framework regions (FR) of about fifteen to thirty amino acids separated by shorter regions of extreme variability called “hypervariable regions” that are each about nine to twelve amino acids long.
  • variable domains of native heavy and light chains each comprise four framework regions, largely adopting a beta-sheet configuration, connected by three hypervariable regions, which form loops connecting, and in some cases forming part of, the beta-sheet structure.
  • the hypervariable regions in each chain are held in close proximity by the framework region and, with the hypervariable regions from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al. (1991) Sequences of Proteins of Immunological Interest, Public Health Service, National Institutes of Health).
  • the constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular cytotoxicity (ADCC).
  • hypervariable region when used herein refers to the amino acid residues of an antibody which are responsible for antigen-binding.
  • the hypervariable region generally comprises amino acid residues from a "complementarity determining region" or "CDR" which contributes to the specificity of the antibody.
  • An antibody also refers to antibodies or fragments thereof that specifically bind to an antigen of interest.
  • antibodies or fragments that immunospecifically bind to a selected antigen do not non-specifically cross-react with other antigens (e.g. , binding cannot be competed away with a different protein, e.g., BSA in an appropriate immunoassay).
  • Antibodies or fragments that immunospecifically bind to an antigen can be identified, for example, by immunoassays or other techniques known to those of skill in the art.
  • Antibodies of the invention include, but are not limited to, synthetic antibodies, monoclonal antibodies, recombinantly produced antibodies, intrabodies, diabodies, multispecific antibodies (including bi-specific antibodies), human antibodies, humanized antibodies, chimeric antibodies, single-chain Fvs (scFv) (including bi- specific scFvs), single chain antibodies, Fab' fragments, F(ab') 2 fragments, disulfide-linked Fvs (sdFv), and anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above.
  • antibodies of the present invention include immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds to a malignant cancer cell marker (e.g., one or more complementarity determining regions (CDRs) of an antibody).
  • a malignant cancer cell marker e.g., one or more complementarity determining regions (CDRs) of an antibody.
  • monoclonal antibody refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e. , the individual antibodies present in the population are identical, except for possible naturally occurring mutations that may be present in minor amounts, and includes antibody fragments as defined herein. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations which include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a specified determinant on the antigen.
  • the term “monoclonal antibody” also encompasses bispecific monoclonal antibodies (BsMAb, BsAb) which are composed of fragments of two different monoclonal antibodies and consequently binds to two different types of antigen.
  • BsMAb, BsAb bispecific monoclonal antibodies
  • the monoclonal antibodies are advantageous in that they may be synthesized uncontaminated by other antibodies.
  • the modifier "monoclonal” is not to be construed as requiring production of the antibody by any particular method.
  • the monoclonal antibodies useful in the present invention may be prepared by the hybridoma methodology first described by Kohler et al. (1975) Nature 256, 495, or may be made using recombinant DNA methods in bacterial, eukaryotic animal or plant cells (see U.S.
  • Patent 4,816,567) The "monoclonal antibodies” may also be isolated from phage antibody libraries using the techniques described in Clackson et al. (1991) Nature 352:624-628, and Marks et al. (1991) J. Mol. Biol. 222, pp. 581-597, for example.
  • an "intact" antibody is one which comprises an antigen-binding site as well as a C L and at least heavy chain constant domains, C m and C m and C H 3.
  • the constant domains may be native sequence constant domains (e.g. , human native sequence constant domains) or amino acid sequence variant thereof.
  • the intact antibody has one or more effector functions.
  • antibody fragment comprises a portion of an intact antibody, preferably the antigen binding CDR or variable region of the intact antibody.
  • antibody fragments include Fab, Fv, Fab' and F(ab') 2 fragments; diabodies; linear antibodies (see U.S. Patent 5,641,870 and Zapata et al. (1995) Protein Eng. 8, pp. 1057-1062); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
  • Papain digestion of antibodies produces two identical antigen-binding fragments, called “Fab” fragments, and a residual "Fc” fragment, a designation reflecting the ability to crystallize readily.
  • the Fab fragment consists of an entire L chain along with the variable region domain of the H chain (V H ), and the first constant domain of one heavy chain (C HI ).
  • Each Fab fragment is monovalent with respect to antigen binding, i.e. , it has a single antigen-binding site.
  • Pepsin treatment of an antibody yields a single large F(ab') 2 fragment which roughly corresponds to two disulfide linked Fab fragments having divalent antigen-binding activity and is still capable of cross-linking antigen.
  • Fab' fragments differ from Fab fragments by having additional few residues at the carboxy terminus of the C M domain including one or more cysteines from the antibody hinge region.
  • Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group.
  • F(ab') 2 antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
  • the Fc fragment comprises the carboxy-terminal portions of both H chains held together by disulfides.
  • the effector functions of antibodies are determined by sequences in the Fc region, which is also the part recognized by Fc receptors (FcR) found on certain types of cells.
  • Fv is the minimum antibody fragment which contains a complete antigen-recognition and -binding site. This fragment consists of a dimer of one heavy- and one light-chain variable region domain in tight, non-covalent association. From the folding of these two domains emanate six hypervariable loops (three loops each from the H and L chains) that contribute the amino acid residues for antigen binding and confer antigen binding specificity to the antibody. However, even a single variable domain (or half of an Fv that comprises only three CDRs specific for an antigen) has the ability to recognize and bind to an antigen, although at a lower affinity than the entire binding site.
  • Single-chain Fv also abbreviated as “sFv” or “scFv” are antibody fragments that comprise the V H and V L antibody domains connected into a single polypeptide chain.
  • the sFv polypeptide further comprises a polypeptide linker between the V H and V L domains which enables the sFv to form the desired structure for antigen binding (see
  • diabodies refers to small antibody fragments prepared by constructing sFv fragments (see preceding paragraph) with short linkers (about 5 to about 10 residues) between the V H and V L domains such that inter-chain but not intra-chain pairing of the V domains is achieved, resulting in a bivalent fragment, i.e., fragment having two antigen-binding sites.
  • Bispecific diabodies are heterodimers of two "crossover" sFv fragments in which the V H and V L domains of the two antibodies are present on different polypeptide chains.
  • Diabodies are described more fully in, for example, WO 93/11161 and Hollinger et al. (1993) Proc. Natl. Acad. Sci.
  • an "isolated antibody” is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous components. In preferred embodiments, the antibody will be purified to greater than 95% by weight of antibody, and most preferably more than 99% by weight. Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, an isolated antibody will be prepared by at least one purification step.
  • the conjugated antibodies used in the methods of the invention include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (see U.S. Patent 4,816,567 and Morrison et al. (1984) Proc. Natl. Acad. Sci. USA 81, pp. 6851-6855).
  • Chimeric antibodies of interest herein include, but are not limited to "humanized” antibodies comprising variable domain antigen-binding sequences derived from a non-human mammal (e.g. , murine) and human constant region sequences.
  • Antibodies of the invention may also comprise a fully human antibody sequence.
  • antibodies of the invention may be a fully human antibody.
  • the invention comprises antibodies, or fragments thereof, which immunospecifically bind to a selected antigen, wherein said antibody is conjugated to a radioisotope via a chelator linkage.
  • Examples include a bifunctional chelant, which is a molecule that has, in addition to chelating functionality, the ability to be conjugated (linked) to a biotargeting molecule (e.g. monoclonal antibody).
  • Examples include, but are not limited to, mono- or dicyclic anhydrides of DTPA (diethylenetriamine pentaacetic acid), TCMC (1, 4,7, 10-tetrakis(carbamoylmethyl)- 1,4,7, 10- tetraazacyclododecane), MeO-DOTA (a-(5-isothiocyanato-2-methoxyphenyl)-l,4,7, 10- tetraazacyclododecane-l,4,7, 10-tetraacetic acid which is a bifunctional chelant) and DOTA ( 1 ,4,7, 10-tetraazacyclododecane- 1 ,4,7, 10-tetraacetic acid), CYEDTA (trans- 1 ,2- diaminocyclohexane-N,N,N',N'-tetraacetic acid) and derivatives thereof.
  • TCMC provides metal complexes with high stability, thereby reducing the incidence of background during imaging procedures or damage
  • the chelate conjugated to the monoclonal antibody is a derivative of the chelate bonded to an organic functional group which serves to link the chelate to the monoclonal antibody. Reacting the chelate derivative and the monoclonal antibody produces the chelate conjugated monoclonal antibodies which can be reacted with 212 Pb radioisotope to produce the 212 Pb-antibody conjugates. These conjugates retain sufficient activity and selectivity of the antibody or antibody fragment.
  • the conjugated antibody binds to an epitope on the cytoplasmic domain of a protein specific to cancer cells (i.e. , a cancer cell marker).
  • a protein specific to cancer cells i.e. , a cancer cell marker
  • malignant cancer cell antigen is defined herein as an antigen that is present in higher quantities on a tumor cell or in body fluids than unrelated tumor cells, normal cells, or in normal body fluid.
  • the antigen presence may be tested by any number of assays known to those skilled in the art and include without limitation negative and/or positive selection with antibodies, such as an ELISA assay, a Radioimmunoassay, or by Western Blot.
  • the conjugated antibody includes, but is not limited to, an antibody which binds to an epitope on the cytoplasmic domain of a tissue antigen selected from the group consisting of HER2 (Human Epidermal Growth Factor Receptor-2), HERl (Human Epidermal Growth Factor Receptor- 1 also known as Epidermal Growth Factor Receptor), CD45, CD25, CD20, CD22, CD 19, CD33, VEGF (Vascular Endothelial Growth Factor), MET (MNNG (N-Methyl-N'-nitro-N-nitroso-guanidine) HOS Tranforming gene also known as Hepatocyte Growth Factor Receptor), CEA (Carcinoembryonic antigen), BRCA1, BRCA2 and IGFR-1 (Insulin-like Growth Factor Receptor- 1).
  • HER2 Human Epidermal Growth Factor Receptor-2
  • HERl Human Epidermal Growth Factor Receptor- 1 also known as Epidermal Growth Factor Re
  • an antibody is the Trastuzumab monoclonal antibody which binds to HER2 as described in U.S. Patent 6, 165,464 which is herein incorporated by reference in its entirety.
  • conjugated antibodies to a number of other antigens also is encompassed in the invention.
  • antibodies to pathogens such as viruses can be conjugated to 212 Pb radioisotope to image and detect viral infections.
  • antibodies to bacterial antigens can be conjugated to 212 Pb radioisotope to image and detect bacterial infections.
  • the pathogens which can be detected include a virus (or an antigen present on the cell surface of infected cells) or bacteria.
  • virus or an antigen present on the cell surface of infected cells
  • Exemplary pathogenic antigens can be found in Ansari (2010) Nucl. Acids Res. 38, D847-853.
  • Exemplary viruses which can be detected according to the methods of the invention include human immunodeficiency virus (HIV), influenza virus, vaccinia virus, human papilloma virus, hepatitis virus (A, B or C) and human parvovirus.
  • HIV human immunodeficiency virus
  • influenza virus influenza virus
  • vaccinia virus human papilloma virus
  • hepatitis virus A, B or C
  • Exemplary bacteria that can be detected according to the methods of the invention include Mycobacterium, Plasmodium, Anaplasma, Brucella, Candida, Helicobacter,
  • Streptococcus Staphylococcus, Haemophilus, Vibrio, Clostridium, Yersinia, Coccidioides, Neisseria, Borrelia, Chlamydia, Shigella, Bacillus, Legionella, Listeria, Pseudomonas, Boophilus, Treponema, Klebsiella, Salmonella and Echinococcus.
  • the invention encompasses a formulation of highly purified 212 Pb for targeting a tumor site. Due to the absence of 224 Ra in the highly purified radioisotope formulation, direct injection into a tumor site will allow for resolution of the tumor.
  • Such formulations may include other agents which complex with 212 Pb to facilitate delivery to the tumor site. Such agents include, but are not limited to, liposomes or colloids.
  • free radioisotope can be administered directly to the tumor site for imaging purposes.
  • liposomes A unique property of liposomes is their natural ability to target tumors due to the enhanced permeability and retention effect in endothelial cells lining the blood vessels of tumors. Liposomes of certain sizes, typically less than 400 nm, can rapidly enter tumor sites from the blood, but are kept in the bloodstream by the endothelial wall in healthy tissue vasculature. Thus, encapsulation of highly purified 212 Pb in liposomes allows for delivery of the radioisotope directly to a tumor site, which can then be used for imaging and/or treating the tumor.
  • the 212 Pb radioisotope is suspended in solution phase to form a colloid.
  • a highly purified 212 Pb radioisotope is suspended in a continuous phase to form a colloid.
  • highly purified 212 Pb radioisotope is synthesized in a colloid and need not be subsequently suspended to form a colloid.
  • the colloid is a sulfur colloid as described in Rotmensch (1989)
  • the present invention includes an in vivo diagnostic procedure that includes introducing the 212 Pb radioisotope conjugated antibody of the invention into the body of a mammal, and allowing sufficient time for the conjugated antibody to localize before imaging.
  • the present invention also includes in vitro analytical procedures employing the conjugated antibody of the invention.
  • the invention encompasses use of any of the radioisotope compositions described herein for imaging a distribution of an antigen associated with a tumor, tissue or pathogen.
  • antibodies, or fragments thereof can be used as diagnostic or detectable agents.
  • the antibody, or fragments thereof can be used as diagnostic or detectable agents.
  • tissue antigen selected from HER2, HER1, CD45, CD25, CD20, CD22, CD 19, CD33, VEGF, MET, CEA, BRCA1, BRCA2 or IGFR-1, wherein said antibody is conjugated to a radioisotope via a chelator linkage.
  • the presence of binding to a tissue antigen indicates the presence of a malignant cancer cell.
  • Antibodies of the invention can be useful for monitoring or prognosing the development or progression of a cancer as part of a clinical testing procedure, such as determining the efficacy of a particular therapy. Additionally, such antibodies can be useful for monitoring or prognosing the development or progression of cancerous conditions.
  • Types of malignant cancer cells which can be detected using the methods of the invention include any malignant cancer cell which expresses one or more of the
  • Types of malignant cancer cells which can be detected using the compositions and methods of the invention include, but are not limited to malignant cancer cells which express of or more of the following antigens: breast (HER2, VEGF & BRCA), ovarian (HER2), stomach
  • the cancer cells can be imaged, and the relative amount of malignant cancer cells can be determined by any available means.
  • the invention includes diagnostic methods to detect cancer and/or assess the effect of therapeutic agents on cancer cells in an organ or body area of a mammal, including a human. Subsequent to administration of the therapeutic agent, an additional amount of detectable monoclonal antibody can be administered to determine the relative amount of cancer cells remaining following treatment. Comparison of the before- and after-treatment images can be used as a means to assess the efficacy of the treatment wherein a decrease in the number of cancer cells imaged following treatment is indicative of an efficacious treatment regimen.
  • pathogens such as viruses or bacteria can be imaged in an infected subject, and the relative amount of pathogens present can be determined by any available means.
  • the invention includes diagnostic methods to detect pathogenic infection and/or assess the effect of therapeutic agents on the infection in an organ or body area of a mammal, including a human.
  • an additional amount of detectable monoclonal antibody can be administered to determine the relative amount of pathogen remaining following treatment. Comparison of the before- and after-treatment images can be used as a means to assess the efficacy of the treatment wherein a decrease in the number of pathogens imaged following treatment is indicative of an efficacious treatment regimen.
  • the pathogens that can be detected include a virus or bacteria.
  • Exemplary pathogenic antigens can be found in Ansari (2010) Nucl. Acids Res. 38, D847-853.
  • Exemplary viruses that can be detected according to the methods of the invention include human immunodeficiency virus (HIV), influenza virus, vaccinia virus, human papilloma virus, hepatitis virus (A, B or C) and human parvovirus.
  • HIV human immunodeficiency virus
  • influenza virus vaccinia virus
  • human papilloma virus human papilloma virus
  • hepatitis virus A, B or C
  • human parvovirus human parvovirus
  • Exemplary bacteria that can be detected according to the methods of the invention include Mycobacterium, Plasmodium, Anaplasma, Brucella, Candida, Helicobacter, Streptococcus, Staphylococcus, Haemophilus, Vibrio, Clostridium, Yersinia, Coccidioides, Neisseria, Borrelia, Chlamydia, Shigella, Bacillus, Legionella, Listeria,
  • the term “detectable amount” refers to the amount of labeled conjugated antibody that binds to a malignant cancer cell antigen when administered to a patient that is sufficient to enable detection of binding of the labeled monoclonal antibody to one or more malignant cancer cells in a tumor.
  • the term “imaging effective amount” refers to the amount of the labeled antibody administered to a patient that is sufficient to enable imaging of binding of the antibody to one or more malignant cancer cells in a tumor.
  • imaging effective amount refers to the amount of labeled antibody administered to a patent that is sufficient to enable imaging of micrometastases, including those of metastatic cancer.
  • the methods of the invention comprise conjugated antibodies which, in conjunction with non-invasive imaging techniques such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT), are used to identify and quantify abnormal cells in vivo including malignant cells in tumors.
  • PET positron emission tomography
  • SPECT single-photon emission computed tomography
  • the term "/ ' « vivo imaging” refers to any method that permits the detection of 212 Pb as described above. In some embodiments, detection of the decay products
  • the radiation emitted from the tumor or area being examined is measured and expressed either as total binding, or as a ratio in which total binding in one tissue is normalized to (i.e. , divided by) the total binding in another tissue or the entire body of the same subject during the same in vivo imaging procedure.
  • the terms "subject” or “patient” refers to a mammal, including a human.
  • conjugated antibodies are useful for in vivo detection and imaging of tumors. These compounds are to be used in conjunction with non-invasive imaging techniques such as positron emission tomography (PET), and single-photon emission computed tomography (SPECT).
  • PET positron emission tomography
  • SPECT single-photon emission computed tomography
  • the conjugated antibody may be labeled (complexed) with 212 Pb using techniques described below or known to those skilled in the art.
  • the inventor encompasses in vivo imaging simultaneous to or followed by treatment with the same conjugated antibody. Specific embodiments include in vivo imaging and treatment with a 212 Pb-TCMC-Trastuzumab.
  • the dosage of the isotopically-labeled monoclonal antibody will vary depending on considerations such as age, condition, sex, and extent of disease in the patient, contraindications, if any, concomitant therapies and other variables, to be adjusted by the skilled artisan. Dosage can vary from 7.4 MBq/m 2 (0.2 mCi/m 2 ) to 370 MBq/m 2 (10.0 mCi/m 2 ) of body surface. Administration to the patient may be local or systemic and accomplished intravenous, intra-arterial, intra-thecal (via the spinal fluid), intra-cranial or the like. Administration may also be intra-dermal or intra-cavitary, depending upon the body site under examination.
  • the area of the subject under investigation is examined by routine imaging techniques such as SPECT, planar scintillation imaging, PET, and emerging imaging techniques.
  • routine imaging techniques such as SPECT, planar scintillation imaging, PET, and emerging imaging techniques.
  • the exact protocol will necessarily vary depending upon factors specific to the patient, as noted above, and depending upon the body site under examination, method of administration and type of label used; the determination of specific procedures would be routine to the skilled artisan.
  • the amount (total or specific binding) of the bound isotopically-labeled monoclonal antibody is measured and compared (as a ratio) with the amount of isotopically-labeled monoclonal antibody bound to the tumor following chemotherapeutic treatment.
  • the conjugated antibodies of the invention can be used for diagnosis and prognosis by using tissues and fluids distal to the primary tumor site (as well as methods using tissues and fluids of the primary tumor and/or tissue and fluids surrounding the tumor).
  • Antibodies of the invention can be used to assay malignant cancer cell antigen levels in a biological sample using classical immunohistological methods as known to those of skill in the art (e.g. , see Jalkanen et al. (1985) J. Cell. Biol. 101, pp. 976-985; and Jalkanen et al. (1987) J. Cell. Biol. 105, pp. 3087-3096).
  • Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA).
  • the present invention provides diagnostic kits, including both immunodetection and imaging kits, for use with the immunodetection and imaging methods described above.
  • the modification of antibodies for the addition of a chelator may be accomplished by formation of a covalent linkage with an amino acid residue of the protein and a functional group of the bifunctional chelator which is capable of binding proteins.
  • the chelator could also be attached to the antibody via a linker molecule (such as biotin for avidin conjugates molecules or a hapten for bispecific mAbs).
  • Suitable chelators include, but are not limited to, TCMC and DOTA.
  • any suitable process that results in the formation of the conjugates of this invention is within the scope of this invention, but incorporation of radionucleotide will exceed 90% given the high purity of the starting radioisotope (e.g. , 212 Pb) material.
  • one important aspect for an efficient reaction is the antibody to conjugate ratio.
  • the conjugate to antibody ratio should be approximately 7: 1, 10: 1, 30: 1, 40: 1, 50: 1, 60: 1, 70: 1, 80: 1, 90: 1, 100: 1, 150: 1, 200: 1, 250: 1, respectively.
  • the pH ofthe reaction mixture should be about 10 to about 5, preferably about 9 to about 8. More preferably the pH should be about 8.5.
  • the conjugation reaction should be carried out at a temperature range from about 20°C to about 37°C. Up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more chelates could be bound to the antibody following the described protocol.
  • the chelator to antibody ratio is about 5 : 1 or greater. In another embodiment, the chelator to antibody ratio is about 7: 1, or greater, with little loss, if any, of immunoreactivity.
  • Binding of a therapeutic radioactive isotope to the bifunctional chelator may be accomplished either with the bifunctional chelator that is not complexed to an antibody or, alternatively, a composition consisting of a chelator conjugated to an antibody.
  • the complexing reaction should be accomplished at a pH of about 7 to about 4, preferably about 6 to about 5. More preferably the pH should be about 5.5.
  • the complexing reaction may be accomplished in an acetate buffer (e.g., ammonium acetate, sodium acetate, potassium acetate). Preferably the molar concentration should be about 100 mM.
  • the complexing reaction should be carried out at a temperature range from about 20°C to about 37°C.
  • the percent of radionucleotide complexed with chelator should be between about 70% and about 100%, preferably, above 90% and even above 95%.
  • the conjugated antibodies of the invention may be administered in vivo in any pharmaceutically acceptable carrier.
  • a physiologic normal saline solution can be used, and may optionally include an appropriate amount of carrier protein, such as human serum albumin (for antibody stabilization).
  • compositions of the invention include bulk drug compositions useful in the manufacture of pharmaceutical compositions (e.g. , impure or non-sterile compositions) and pharmaceutical compositions (i.e. , compositions that are suitable for administration to a human) that can be used in the preparation of unit dosage forms.
  • Such compositions include an amount of agent disclosed herein or a combination of those agents effective for imaging and a
  • compositions of the invention include an effective amount of one or more antibodies of the invention and a pharmaceutically acceptable carrier.
  • the term "pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
  • carrier refers to a diluent or vehicle with which the therapeutic is administered.
  • Such pharmaceutical carriers can be sterile liquids, such as water, saline, or buffers containing any combination of the following components: sugars, amino acids, detergents, antioxidants, metal chelators, alcohol and/or inorganic salts.
  • the compositions of the invention can be formulated as neutral or salt forms.
  • Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.
  • agents of the invention useful for imaging malignant cancer cells, e.g. , encapsulation in liposomes, microparticles or microcapsules.
  • Methods of administering agents of the invention include, but are not limited to, parenteral administration (e.g. , intradermal, intramuscular, intraperitoneal, intravenous and subcutaneous).
  • agents of the invention are administered to a patient.
  • the agents may be administered intravenously.
  • the agents may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g. , oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local.
  • WO20081 13792 Purified 212 Pb is then used as follows to produce 212 Pb-TCMC-Trastuzumab.
  • the glass vial containing the 212 Pb generator eluate is placed on a stir/heat plate set at 100°C under a 250 watt heating lamp shining directly on the borosilicate glass vial. Allow the generator eluate in the borosilicate glass to evaporate completely with gentle stirring. After eluate evaporation, the glass vial is placed in a lead pig and allowed to cool down for approximately one minute. Add 1.5 ml of 8N HN0 3 to the borosilicate glass vial containing the 212 Pb.
  • QC samples are removed and tests conducted by ITLC, HPLC, HER2 binding and gel electrophoresis.
  • the final solution is sterile filtered into a sterile vial. Samples are submitted for endotoxin and sterility testing.
  • the radioactivity content of the purified drug is evaluated using an AREVA Canberra HpGe detector.
  • the TCMC-Trastuzumab starting material enables 90+% yields based on 212 Pb content (decay-corrected) using the radiosynthetic procedure outlined above. QC of the 212 Pb-TCMC- Trastuzumab can be achieved relatively quickly, and the material is stable over the time period required prior to injection.
  • Planar gamma camera images were analyzed using ImageJ (version 1.43).
  • a first phantom was built by assembling a 30 mL vial as the heart containing 2.8 MBq (75 ⁇ ) of 212 Pb, a 250 mL saline bag with 3.2 MBq (87 ⁇ ) as the peritoneal cavity, two 15 mL vials with 0.7 and 0.8 MBq (20 and 23 ⁇ ) for the kidneys (Figure 1) and imaged to confirm that the discernable phantom organs could be detected ( Figure 2).
  • a new phantom study was conducted to match the size of the peritoneal phantom organ with that of the NHPs used in the study.
  • the average weight of the peritoneal organs for the NHPs used in the studies was 385 grams.
  • Phantom images are presented in Figure 3 and NHP images in Figure 5. All images were collected with a gamma camera equipped with a parallel-hole, high-energy collimator (Picker Axis SPECT camera) until 500,000 counts were detected, and for that reason, they appear similar over the 48-hour experiment.
  • a parallel-hole, high-energy collimator Pieric Axis SPECT camera
  • Figure 6 shows (top) planar images of three C57BL/6 female mice imaged simultaneously in planar mode on the ⁇ SPECT/CT camera with medium energy collimators at to, h, and t 8h post IP injection of 212 Pb-TCMC-Trastuzumab; (bottom) single C57BL/6 female mouse imaged on the ⁇ SPECT/CT camera at to, h, and t 8h post IP injection of 212 Pb-TCMC-Trastuzumab.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne une composition radio-pharmaceutique qui comprend un isotope radioactif de combinaison de plomb (212Pb) avec une substance pharmaceutique ou un anticorps ou un fragment d'anticorps et un agent de chélation. Ces compositions sont particulièrement utilisées dans l'imagerie et le diagnostic de tumeurs et de métastases tumorales.
PCT/EP2011/065388 2010-09-07 2011-09-06 Imagerie 212 pb Ceased WO2012032043A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38062910P 2010-09-07 2010-09-07
US61/380,629 2010-09-07

Publications (1)

Publication Number Publication Date
WO2012032043A1 true WO2012032043A1 (fr) 2012-03-15

Family

ID=44645688

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/065388 Ceased WO2012032043A1 (fr) 2010-09-07 2011-09-06 Imagerie 212 pb

Country Status (1)

Country Link
WO (1) WO2012032043A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017220767A1 (fr) * 2016-06-24 2017-12-28 Sciencons AS Préparation d'anticorps monoclonaux marqués au pb212
CN107530456A (zh) * 2015-02-26 2018-01-02 塞控斯公司 具有优异特性的放射性药物溶液

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1993011161A1 (fr) 1991-11-25 1993-06-10 Enzon, Inc. Proteines multivalentes de fixation aux antigenes
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6165464A (en) 1988-01-12 2000-12-26 Genetech, Inc. Monoclonal antibodies directed to the HER2 receptor
WO2008113792A2 (fr) 2007-03-19 2008-09-25 Areva Nc Production de thorium 228 à partir d'un sel de thorium naturel
WO2008115854A2 (fr) * 2007-03-19 2008-09-25 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Nanoparticules multifonctions, compositions et procédés d'utilisation correspondants
WO2009012288A2 (fr) * 2007-07-17 2009-01-22 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Agent d'imagerie trifonctionnelle pour l'imagerie ciblée de tumeur par anticorps monoclonaux

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6165464A (en) 1988-01-12 2000-12-26 Genetech, Inc. Monoclonal antibodies directed to the HER2 receptor
WO1993011161A1 (fr) 1991-11-25 1993-06-10 Enzon, Inc. Proteines multivalentes de fixation aux antigenes
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
WO2008113792A2 (fr) 2007-03-19 2008-09-25 Areva Nc Production de thorium 228 à partir d'un sel de thorium naturel
WO2008115854A2 (fr) * 2007-03-19 2008-09-25 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Nanoparticules multifonctions, compositions et procédés d'utilisation correspondants
WO2009012288A2 (fr) * 2007-07-17 2009-01-22 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Agent d'imagerie trifonctionnelle pour l'imagerie ciblée de tumeur par anticorps monoclonaux

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
ANSARI, NUCL. ACIDS RES., vol. 38, 2010, pages D847 - 853
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
JALKANEN ET AL., J CELL. BIOL., vol. 101, 1985, pages 976 - 985
JALKANEN ET AL., J CELL. BIOL., vol. 105, 1987, pages 3087 - 3096
KABAT ET AL.: "Sequences ofProteins oflmmunological Interest", 1991, NATIONAL INSTITUTES OF HEALTH
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
MARKS ET AL., J MOL. BIOL., vol. 222, 1991, pages 581 - 597
MILENIC D E ET AL: "Multimodality therapy: Potentiation of high linear energy transfer radiation with paclitaxel for thetreatment of disseminated peritoneal disease", CLINICAL CANCER RESEARCH 20080815 US LNKD- DOI:10.1158/1078-0432.CCR-08-0256, vol. 14, no. 16, 15 August 2008 (2008-08-15), pages 5108 - 5115, XP002665302, ISSN: 1078-0432 *
MILENIC DIANE E ET AL: "Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 15 MAR 2007 LNKD- PUBMED:17363549, vol. 13, no. 6, 15 March 2007 (2007-03-15), pages 1926 - 1935, XP002665303, ISSN: 1078-0432 *
MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855
ROSENBURG ET AL.: "The Pharmacology ofmonoclonal Antibodies", 1994, SPRINGER-VERLAG, pages: 269 - 315
ROTMENSCH, GYNECOLOGIC ONCOLOGY, vol. 32, 1989, pages 236 - 239
ZAPATA ET AL., PROTEIN ENG., vol. 8, 1995, pages 1057 - 1062

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107530456A (zh) * 2015-02-26 2018-01-02 塞控斯公司 具有优异特性的放射性药物溶液
WO2017220767A1 (fr) * 2016-06-24 2017-12-28 Sciencons AS Préparation d'anticorps monoclonaux marqués au pb212
CN109310789A (zh) * 2016-06-24 2019-02-05 塞控斯公司 制备212Pb标记的单克隆抗体
JP2019523232A (ja) * 2016-06-24 2019-08-22 サイエンコンス アクスイェ セルスカプ ２１２Ｐｂ標識モノクローナル抗体の調製
CN109310789B (zh) * 2016-06-24 2021-12-03 塞控斯公司 制备212Pb标记的单克隆抗体
US11306038B2 (en) 2016-06-24 2022-04-19 Sciencons AS Preparation of 212Pb labeled monoclonal antibodies
JP7176958B2 (ja) 2016-06-24 2022-11-22 サイエンコンス アクスイェ セルスカプ ２１２Ｐｂ標識モノクローナル抗体の調製
AU2017281649B2 (en) * 2016-06-24 2023-07-27 Sciencons AS Preparation of 212Pb labeled monoclonal antibodies
IL263808B2 (en) * 2016-06-24 2025-04-01 Sciencons AS Preparation of 212PB-labeled monoclonal antibodies

Similar Documents

Publication Publication Date Title
JP4354280B2 (ja) Ｒｓ７抗体
JP5110768B2 (ja) モノクローナル抗体ｐａｍ４ならびに膵臓癌の診断および治療のためのその使用
US20250345466A1 (en) Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy
JP5855209B2 (ja) 放射免疫コンジュゲートおよびその使用
JPH05502236A (ja) 感染性及び炎症性病変の検出及び治療のためのキメラ抗体
RU2741794C2 (ru) Радиофармацевтические растворы с предпочтительными свойствами
Foubert et al. Sensitivity of pretargeted immunoPET using 68Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: comparison with 18FDG PET-CT
US20100047167A1 (en) Combination therapy in the treatment of cancer
Mohsin et al. Comparison of pretargeted and conventional CC49 radioimmunotherapy using 149Pm, 166Ho, and 177Lu
Takashima et al. Tumor targeting of 211At-labeled antibody under sodium ascorbate protection against radiolysis
JP2009292815A (ja) 腫瘍診断に使用するための抗−Ｍｅｔモノクローナル抗体、そのフラグメントおよび誘導体、対応する組成物およびキット
WO2012032043A1 (fr) Imagerie 212 pb
Goldsmith et al. An overview of the diagnostic and therapeutic use of monoclonal antibodies in medicine
US20230293738A1 (en) B7H3 Antibodies with Chelators
ZA200704642B (en) Radiation dosimetry and blocking antibodies and methods and uses therefor in the treatment of cancer
US20250152760A1 (en) Radioactive complex of anti-vegf antibody, and radiopharmaceutical
US20230390425A1 (en) Radioactive complexes of anti-her2 antibody, and radiopharmaceutical
KR20250147080A (ko) 방사성동위원소가 표지된 항-her2 항체-킬레이터 접합체, 이를 포함하는 약학적 조성물 및 이의 제조방법
WO2024215718A2 (fr) Véhicules thérapeutiques à particules alpha ciblant le cancer pour le traitement du cancer
Zanzonico et al. Positron Emission Tomography (PET)-based Compartmental Modeling of 124I-A33 Antibody: Quantitative Characterization of Patient-specific Tumor Targeting in Colorectal Cancer
CN120826245A (zh) 将生物制剂与多种螯合剂组合的方法和材料
Cederkrantz Pharmacokinetics and dosimetry in intraperitoneal radioimmunotherapy with 211At
John Analysis of biodistribution and therapeutic efficacy of a novel labeled antibodies based technique in the treatment of cancer with mice model
Cheung et al. Pharmacokinetics of Genetically Engineered Antibody Forms Using Positron Emission Tomography
JPH06509102A (ja) 体内造影抗イディオタイプ抗体を用いた組織特異的造影剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11755308

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11755308

Country of ref document: EP

Kind code of ref document: A1